Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Could Rebound If $2.80 Support Holds After 2B Coins Cluster, Data Suggests

XRP Could Rebound If $2.80 Support Holds After 2B Coins Cluster, Data Suggests

CoinotagCoinotag2025/09/15 18:42
By:Marisol Navaro

  • Largest holder cluster: $2.80

  • Short-term technicals (TD Sequential on 4H) show a fresh buy signal; $16M in liquidations reset positions.

  • Recent price action: brief $3.10 high, trending down since August, with repeated buying near $2.80.

XRP $2.80 support is key — watch confirmed holds for a rebound to $3.05–$3.15; read the analysis and actionable levels.






What is the significance of XRP’s $2.80 support level?

XRP $2.80 is the largest on-chain holder cluster right now, with Glassnode reporting over 2,000,000,000 XRP purchased at that price. This concentration—about $6 billion in notional value—creates a high-impact support zone where breaking below would likely increase selling pressure.

How has XRP traded around $2.80 recently?

Price action since August shows repeated approaches to $2.80 with buying near that band. XRP briefly traded above $3.10 in early September but retreated to sub-$3.00 levels shortly after.

The on-chain heatmap highlights concentrated supply at $2.80, indicating where holders are clustered and where buy-side defense has occurred historically. Glassnode and market heatmap visuals are cited as data sources (plain text).

How likely is a short-term recovery if $2.80 holds?

Short-term indicators support at least a corrective bounce. The TD Sequential on the four-hour chart signaled a buy, per analyst Ali Martinez. Additionally, more than $16 million in liquidations occurred in the last 24 hours, mostly long positions, which can reduce immediate upside pressure.

If $2.80 remains intact, upside targets appear at $3.05 and $3.15 with limited resistance in the near term. A sustained close below $2.80 raises the next support test near $2.64 and would indicate weakening confidence.

Frequently Asked Questions

Why is a clustered holder level important for XRP?

Clustered holder levels show where many addresses acquired coins. High concentration means those holders are psychologically and financially invested at that price, so a breach can trigger stop-losses and larger sell-offs, increasing downside momentum.

What do recent liquidations tell traders about XRP momentum?

Large liquidations—over $16M recently—imply position resets. When many longs are removed, markets can find a cleaner base for new buying; however, the effect depends on whether buyers step in at the $2.80 cluster.

How should traders use the $2.80 level in risk management?

Use $2.80 as a reference for stop placement, partial profit-taking, or scaling entries. Confirm holding with a daily close above the level for bullish bias; use breaks below $2.80 to reassess position size and exposure.


Key Takeaways

  • $2.80 cluster: Glassnode shows >2,000,000,000 XRP bought at $2.80—~$6B in notional value.
  • Short-term relief possible: TD Sequential (4H) flashed a buy; recent $16M of liquidations may reset positions.
  • Trade plan: Favor confirmed holds above $2.80 for a rebound to $3.05–$3.15; use breaks below $2.80 to reduce risk toward $2.64.

Conclusion

Concentration of holdings at $2.80 makes this price level the defining pivot for XRP in the near term. Data from on-chain heatmaps and Glassnode, combined with short-term technicals and liquidation metrics, provide a clear framework for traders. Monitor confirmed closes and orderbook momentum; if $2.80 holds, expect measured upside toward $3.05–$3.15, while a decisive break would shift focus to lower support near $2.64. COINOTAG will continue tracking on-chain and market signals.

In Case You Missed It: XRP May Need to Hold $3 to Avoid Slipping Toward $2.80–$2.90, Bollinger Bands Suggest
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs